Figure 4
From: Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut
Anti-tumor necrosis factor-α (TNF-α) treatment enhances interleukin (IL)-25 production in inflammatory bowel disease (IBD) tissue. (a) Mucosal samples were collected from the inflamed colon of three patients with Crohn's disease (CD) and four patients with ulcerative colitis (UC) and cultured with infliximab or control IgG for 24 h. Total proteins were then extracted and analyzed for IL-25 content by enzyme-linked immunosorbent assay (ELISA). Each point represents the value of IL-25 protein in mucosal samples taken from a single patient and treated with control IgG or infliximab. Horizontal bars indicate the median; *P=0.015. (b) Mucosal samples were collected from five CD patients and one UC patient immediately before and after a successful treatment with infliximab and used to extract total proteins. IL-25 was analyzed by ELISA. Each point represents the value of IL-25 protein in mucosal samples taken from a single patient before and after infliximab therapy. Horizontal bars indicate the median; *P=0.030.
